NewsNovo
The case for focus comes at a price.
Mission Therapeutics has agreed to let Dimerix Ltd take over development of MTX652, an Acute Kidney Injury asset, under a deal worth up to $292 million, repositioning around a central nervous system pipeline in the process.
The complication: that $292 million is the ceiling on what Mission can ever recover from a program it originated, while Dimerix holds the uncapped upside if the drug works.
The asset that changed hands MTX652 targets Acute Kidney Injury. Dimerix Ltd will now carry the development responsibility, taking on the capital requirements and clinical risk that Mission was previously carrying.
Keep reading